



Pain and overall quality of life in palliatively treated colorectal cancer patients 1 year after diagnosis– results from the EDIUM cohort

Sophie Klara Schellack¹ · Clara Breidenbach¹ · Christoph Kowalski¹ · Ulrich Wedding² · Birgitt van Oorschot³ · Thomas Seufferlein⁴ · Stefan Benz⁵ · Martin Schnell⁶ · Jörg Köninger⁷ · Christina Klein⁸ · Johann Ockenga⁹ · Björn Freitag¹⁰ · Uwe A. Wittel¹¹ · Roger Wahba¹² · Mia Kim¹³ · Saleem Elhabash¹⁴ · Pompiliu Piso¹⁵ · Dirk Weyhe¹⁶ · Jörg Bunse¹⁷ · Maren Riechmann¹⁸ · Marco von Strauss¹⁹ · Sebastian Petzoldt²⁰ · Philipp-Alexander Neumann²¹ · Vanessa Kolb²² · Nora Tabea Sibert^{1,23}

Received: 3 February 2025 / Accepted: 24 March 2025 / Published online: 31 March 2025
© The Author(s) 2025

Abstract

Purpose Diagnosis with UICC stage IV colorectal cancer often indicates palliative treatment to alleviate symptoms. Data on pain in these patients are still scarce but can help improve symptom management. This study therefore aimed to describe patient-reported pain and quality of life.

Methods 147 palliatively treated stage IV colorectal cancer patients diagnosed between 2018 and 2023 completed the EORTC QLQ-C30 and QLQ-CR29 before and 12 months after treatment initiation within the EDIUM study. Descriptive results for pain and quality of life were examined and compared to reference values. A logistic regression analysis investigated the relationship between quality of life and pain and 1-year survival.

Results The mean (SD) for the “overall pain” score was 26 (32) (T0) and 35 (32) (T1) for rectal cancer patients and 34 (33) (T0) and 35 (32) (T1) for colon cancer patients. This is higher than the reference value (24 (30)) and indicates high average pain levels. The “overall quality of life” score showed means below the reference value (61 (23)), indicating poorer quality of life (colon: 51 (25) (T0), 56 (22) (T1); rectum: 52 (24) (T0), 51 (22) (T1)). Higher pain levels persisted at both time points, with no patients reporting absence of pain. The logistic regression results suggest a small relationship between pain and quality of life and 1-year survival.

Discussion This study reveals high levels of pain among palliatively treated colorectal cancer patients, impacting their quality of life. Effective pain management and close monitoring are necessary to improve the quality of life for these patients.

Trail number DRKS00008724.

Keywords Palliative care · Colorectal neoplasms · Patient reported outcomes · Pain · Quality of life

Background

Colorectal cancer (ICD-10 C18-C20) is one of the most common cancers in Germany. Approximately 55,000 new cases are diagnosed each year in Germany, with approximately 24% of the female and 26% of the male patients being diagnosed with UICC stage IV, indicating distant metastases of the primary tumour (Robert Koch-Institut 2023).

Clinical guidelines for metastatic cancer define prolongation of survival, alleviation of the symptoms, and improvement of quality of life as the primary aims when complete

surgical resection of the tumour cannot be achieved. In these cases, palliative care– either with or without tumour-directed therapy– is often the preferred choice of treatment (German Guideline Program in Oncology 2019; Sanders et al. 2024). The oncological S3 guideline for palliative care sets out the principles of care for patients with incurable cancer, including a symptom-specific treatment approach (German Guideline Programme in Oncology 2015).

For cancer patients, pain is a major concern, and dealing with pain can interfere with daily activities and limit quality of life (Kenzik et al. 2015; Rodriguez et al. 2019).

Patient-reported outcomes (PROs) are important measures for assessing outcomes such as pain. PROs are outcomes reported by patients themselves, using validated paper or online questionnaires. They measure the subjective status of symptoms and functions before, after, or during a therapeutic intervention, can serve as a complement to therapeutic success, and are therefore increasingly important for medical care (Di Maio et al. 2022). Since one goal of care defined in the oncologic guidelines for palliatively treated patients is to improve patients' quality of life, the assessment of PROs is the gold standard for adequately managing symptoms. Studies report heterogeneous frequencies of colorectal cancer patients experiencing pain, with a lack of studies that focus particularly on pain symptoms in palliative colorectal cancer patients (Drury et al. 2017; Zielińska et al. 2021).

This study aims to describe pain in palliatively treated stage IV colorectal cancer patients at baseline and 1 year after diagnosis.

Methods

EDIUM study

The EDIUM study ("Outcome Quality in Colorectal Cancer: Identification of Differences and Measures for Nationwide Quality Development") is an ongoing multicentre prospective observational study in Colorectal Cancer Centres that are certified in accordance with the requirements of the German Cancer Society, with the goal of comparing the quality of care for colorectal cancer patients between centres. Study data include functional and symptomatic outcomes as part of the PRO questionnaires used in the study, and clinical end points based on quality assurance data reported as part of the certification process. Currently, data from more than a hundred Colorectal Cancer Centres enrolling their patients in the EDIUM study are available. Details of the EDIUM study are available elsewhere (Kowalski et al. 2022).

Study population

This subgroup analysis focused on palliatively treated stage IV colorectal cancer patients in Germany. The study population consists of colorectal cancer patients treated in Colorectal Cancer Centres enrolled in the EDIUM study. Patients included in the EDIUM study are asked to complete a baseline questionnaire prior to the initiation of any treatment (T0) and another questionnaire 12 months after the start of treatment (T1). The questionnaires include sociodemographic questions as well as the European Organisation for Research and Treatment of Cancer (EORTC) quality of

life questionnaire EORTC QLQ-C30 and the EORTC QLQ-CR29 (Giesinger et al. 2020; Whistance et al. 2009). The assessment time points (T0, T1) as well as the set of PROs for colorectal cancer patients were chosen based on the ICHOM recommendations and the EORTC Manual for the use of EORTC measures in daily clinical practice (Wintner et al. 2016; Zerillo et al. 2017).

Only palliatively treated patients in stage IV without tumour resection who had completed both questionnaires at T0 and T1 were analysed in this study (Fig. 1). Additionally, patients who did not fill out T1 or died within the 12-month period before it were analysed separately.

Outcomes

To address pain in palliatively treated colorectal cancer patients, both the total pain score from the C30 and the colorectal cancer-specific pain scores, as well as the corresponding single items were examined. The C30 "pain" score consists of two items (9: "pain" and 19: "Interference with daily activities due to pain"). The response scale for all pain items comprises "not at all", "a little", and "quite a bit" to "very much" and is converted into score values ranging between 0 and 100, with higher values indicating more severe pain (Aaronson et al. 1993). The CR29 colorectal cancer-specific pain items address "dysuria" (34), "abdominal pain" (35), and "buttock pain" (36) during the previous week. These items are also converted into scores ranging between 0 and 100, with higher values indicating more severe pain. In addition, overall quality of life is assessed, which also consists of two items (29: "global health status" and 30: "overall quality of life"), ranging between 0 and 100, with a higher value indicating a better status (Whistance et al. 2009). The calculation of the raw score and the linear transformation of the items was applied according to the EORTC QLQ-C30 Scoring Manual (Fayers et al. 2001).

To identify clinically relevant changes in function and symptoms, minimally important differences (MIDs) have been established for many PROs. MIDs represent the smallest difference in symptom or functional scores that are noticeable for the patient. For the present study, we followed the suggestion by Musoro et al. to choose 10 points as the MID for C30 and CR29 scores for advanced colorectal cancer patients (Musoro et al. 2020). Reference values were also used to compare the scores as recommended by the EORTC QLQ-C30 Scoring Manual (Fayers et al. 2001; Scott et al. 2008; Whistance et al. 2009).

We also examined the survival of patients within the study period between T0 and T1 by using the documented dates of death in the EDIUM study database.




Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) chart for the EDIUM study sample

Statistical analysis

Descriptive results include relative and absolute frequencies with mean and standard deviations for T0 and T1. For all selected EORTC QLQ-C30 and -CR29 items, raw scores as well as transformed scores are reported. The participants' characteristics are reported stratified by colorectal cancer localization. The dropout cohort between T0 and T1 was investigated to detect differences in participants' characteristics and reported pain compared to the patients who completed the questionnaire at T1 (Appendix Tables S1 and S2). To investigate the correlation between quality of life and pain at T1, Pearson's correlation coefficient was analysed. Logistic regression analysis was performed to examine the relationship between quality of life and pain at T0 and 1-year survival (adjusted for age, educational level, gender, insurance status). The model performance was examined using the AIC, BIC, and Tjur's R^2 . A p value < 0.05 was interpreted as statistically significant. Analysis was performed using the R statistical software program, version 4.3.1, using the "gtsummary", "ggsankey" and "performance" packages (Lüdtke et al. 2021; Sjöberg 2021; Sjöberg et al. 2020).

Results

Study characteristics

The sample for this analysis consisted of 147 palliatively treated colorectal cancer patients aged between 40 and 90 years. Eighty per cent of the patients were over the age of 60, and over 70% were male. Their mean ages were 65 (10) years in colon cancer patients and 68 (9) years in rectal cancer patients. In both groups, most study participants had a certificate from a lower secondary school as their highest school-leaving qualification (colon: 75%, rectum: 78%). Details of the study cohort characteristics are shown in Table 1.

Pain and quality of life

The descriptive results show different trends in pain levels for colon and rectal cancer patients. Rectal cancer patients had higher "buttock pain" levels (mean: 33 (SD 36)) than colon patients at T0, which decreased at T1 (mean: 24 (SD: 32)). In contrast, "buttock pain" levels among colon cancer patients showed an increase at T1: the mean for "buttock pain" in colon cancer patients increased from 10 (SD: 23) to 19 (SD: 28). "Abdominal pain" decreased in both rectal

Table 1 Characteristics of the study cohort

Characteristics	Colon cancer patients (n = 66)	Rectal cancer patients (n = 81)
Age ^{1, 2}		
40–49	3 (4.5%)	2 (2.5%)
50–59	15 (23%)	8 (9.9%)
60–69	25 (38%)	34 (42%)
70–79	17 (26%)	31 (38%)
> 79	6 (9.1%)	6 (7.4%)
Gender ²		
Female	17 (26%)	17 (21%)
Male	49 (74%)	64 (79%)
Highest school education ²		
Higher secondary school	13 (21%)	13 (17%)
Lower secondary school	46 (75%)	60 (78%)
None	1 (1.6%)	1 (1.3%)
Other	1 (1.6%)	3 (3.9%)
Unknown	5	4
Insurance status ²		
Statutory health insurance	55 (89%)	67 (88%)
Private health insurance	6 (9.7%)	7 (9.2%)
Other/none	1 (1.6%)	2 (2.6%)
Unknown	4	5

¹ Mean (SD); ² n (%)

and colon cancer patients. The mean for “dysuria” increased slightly in rectal cancer patients (T0: 4 (SD 13), T1: 8 (SD 19)), but remained stable in colon cancer patients. The overall “pain” score showed a higher increase in rectal cancer patients (T0: 26 (32), T1: 35 (32)) than in colon cancer patients (T0: 34 (33), T1: 35 (32)).

The overall quality of life levels remained stable in both groups. Analyses showed a moderate negative correlation between pain and quality of life both at T0 ($r(144) = -0.48$, $p < 0.001$) and at T1 ($r(145) = -0.49$, $p < 0.001$) (Table 2).

Comparison with the QLQ-C30 and -CR29 reference values showed that the study participants’ quality of life scores were below the reference value (cut-off: 61) for both patient groups at both measurement times. At T0 and T1, the mean total “pain” score was above the cut-off (24) for both groups. Changes in pain and quality of life at T1 were below the MID of 10 points (Musoro et al. 2020).

Figure 2 shows the development of pain symptoms for T0 and T1 for the items “pain”, “interference with daily activities”, “abdominal pain”, “buttock pain”, and “dysuria”, in Sankey plots. None of the colorectal cancer patients reported having no pain at all at either of the two time points. “Interference with daily activities” showed the highest increase: 44% of colon cancer patients reported having more than a little interference with daily activities due to pain at T0, increasing to 57% at T1. In rectal cancer patients,

Table 2 EORTC QLQ-C30 and -CR29: quality of life and pain levels at T0 and T1. The pain score consists of the two items “interference with daily activities, last week” and “pain, last week”. The quality of life score consists of the two items “global health status” and “overall quality of life. The scores for abdominal pain, buttock pain, and dysuria are converted from the corresponding items. A higher value for the pain scores indicates more severe pain, and a higher value for the quality of life score indicates a better quality of life status (both ranging from 0 to 100)

	Colon cancer patients (n = 66)		Rectal cancer patients (n = 81)	
	T0	T1	T0	T1
Quality of life ^{1, *}	51 (25)	56 (22)	52 (24)	51 (22)
Unknown	0		1	
Pain ^{1, *}	34 (33)	35 (32)	26 (32)	35 (32)
Pain, last week ²				
Not at all	0	0	0	0
A little	23 (40%)	25 (42%)	42 (56%)	29 (40%)
Quite a bit	20 (35%)	20 (33%)	17 (23%)	29 (40%)
Very much	14 (25%)	15 (25%)	16 (21%)	15 (21%)
Unknown	9	6	6	8
Interference with daily activities, last week ²				
Not at all	0	0	0	0
A little	32 (56%)	24 (44%)	48 (68%)	31 (44%)
Quite a bit	11 (19%)	18 (33%)	12 (17%)	26 (37%)
Very much	14 (25%)	13 (24%)	11 (15%)	13 (19%)
Unknown	9	11	10	11
Abdominal pain ^{1, *}	33 (34)	29 (30)	21 (28)	18 (24)
Abdominal pain, last week ²				
Not at all	0	0	0	0
A little	27 (46%)	28 (44%)	46 (58%)	46 (58%)
Quite a bit	20 (34%)	21 (33%)	21 (27%)	27 (34%)
Very much	12 (20%)	14 (22%)	12 (15%)	7 (8.8%)
Unknown	7	3	2	1
Buttock pain ^{1, *}	10 (23)	19 (28)	33 (36)	24 (32)
Unknown	1	0	1	0
Buttock pain, last week ²				
Not at all	0	0	0	0
A little	52 (81%)	41 (64%)	38 (54%)	47 (62%)
Quite a bit	7 (11%)	14 (22%)	15 (21%)	14 (18%)
Very much	5 (7.8%)	9 (14%)	18 (25%)	16 (21%)
Unknown	2	2	10	4
Dysuria ^{1, *}	4 (13)	4 (12)	4 (13)	8 (19)
Unknown	1	0	0	1
Dysuria, last week ²				
Not at all	0	0	0	0
A little	58 (89%)	59 (89%)	73 (90%)	66 (84%)
Quite a bit	6 (9.2%)	6 (9.1%)	6 (7.4%)	10 (13%)
Very much	1 (1.5%)	1 (1.5%)	2 (2.5%)	3 (3.8%)
Unknown	1	0	0	2

¹ Mean (SD); ² n (%); * converted score

the interference of pain with their daily activities showed an increase from 32 to 56% at T1 (Fig. 2).

To examine the differences between the patients who were able to complete the T1 questionnaires and those who died




Fig. 2 Sankey diagram for pain items from the EORTC QLQ-CR29 and C30 in colorectal cancer patients at T0 and T1. a, Pain ($n=120$); b, interference with daily activities ($n=112$); c, abdominal pain

($n=135$); d, buttock pain ($n=129$); e, dysuria ($n=144$). The Sankey diagrams only include colorectal cancer patients who responded to the item at T0 and T1

within 12 months ($n=186$), logistic regression analysis was conducted, with 1-year survival (yes vs. no) as the dichotomized outcome. The logistic regression for overall quality of life (T0) and survival showed a relationship indicating

higher odds of 1-year survival with a higher quality of life (T0) (adjusted OR=0.98, $p<0.01$, Tjur's $R^2=0.16$). For pain (T0) as the predictor, logistic regression also indicated higher odds of 1-year survival with lower pain levels (T0)

(adjusted OR=1.01, $p<0.01$, Tjur's $R^2=0.16$). Details of the logistic regression are shown in Table S3.

Dropout analysis

The results of the dropout analysis showed that patients who did not complete the questionnaire 12 months after treatment initiation, although still alive, did not differ significantly from those who answered the T1 questionnaire regarding participants' characteristics, or in pain levels at T0 (Appendix Tables S1 and S2).

Discussion

Overall, these results highlight the symptomatic burden of pain that palliatively treated colorectal cancer patients face before and 12 months after the initiation of treatment. No patients reported that they were free of pain at either T0 or T1. Pain at T0 predicted survival at T1, but the results need to be interpreted with caution due to the smallness of the sample and the lack of potential confounding variables. It also remains unclear whether the reported pain is caused by cancer symptoms, treatment, or other comorbidities.

Some of the descriptive findings deserve highlighting. The highest increase can be seen in the reporting of "interference with daily activities due to pain" for both colon and rectal cancer patients. Although there were changes in the individual pain items in both groups, "overall quality of life" did not differ substantially in either group. Taking the published reference MID's into account (Musoro et al. 2020), the changes in pain and quality of life scores between T0 and T1 were not clinically relevant, but the reference values for "pain" were exceeded in the study population and reduced for "overall quality of life".

The study results illustrate the very substantial burden of pain for palliatively treated colorectal cancer patients, which affects patients' quality of life, as previous research has shown (Rodriguez et al. 2019). The results of the correlation analysis are consistent with previous research showing a moderate negative correlation between pain and quality of life, indicating that lower pain levels are associated with a higher quality of life at both time points. These results are in line with the results of the meta-analysis by Flyum et al. (Flyum et al. 2021). Sociodemographic as well as clinical variables were associated with the health-related quality of life, indicating the importance of tailoring a treatment plan to the patients' symptoms (Flyum et al. 2021). As part of the present study, we evaluated the stoma status in rectal cancer patients along with their pain symptoms. The analysis did not show any statistically significant differences between

patients with and without a stoma at T1 (results available on request).

Forty-four per cent of the palliatively treated patients who had completed the T0 questionnaire and for whom death was documented passed away within the 1-year follow-up period. The presented findings are in line with known colorectal cancer epidemiology (Robert Koch-Institut 2023; Wilson et al. 2023). In addition, the results of the dropout analysis, which analysed the study participants' characteristics and pain levels, did not show any significant differences between patients who completed the T1 questionnaire and those who did not.

The results of the logistic regression analysis show a small relationship between pain/overall quality of life and survival. With adjustment of the models for relevant confounders, thus improving the goodness of fit, however, the relatively low R^2 suggests that there are many other factors besides pain or quality of life that might explain the variation in survival.

To the best of our knowledge, this is one of the first studies to investigate pain specifically in palliatively treated colorectal cancer patients. The detailed results for surgically treated colorectal cancer patients published by Kowalski et al. showed that they had a lower mean "pain" score than the palliative subgroup presented here (Kowalski et al. 2022).

The management of pain in palliative care is a complex challenge that requires interdisciplinary approaches, as has already been stated for other end-stage diseases (Raina et al. 2018). It is important to monitor pain symptoms regularly to flexibly adapt to the patient's pain status. In view of the wide range of pain types investigated by the present study and the fact that a high symptom burden was observed for all types of pain, the results confirm the need for an interdisciplinary approach. Palliative care for cancer patients should be tailored to the needs of the patient—by evaluating PROs in palliative cancer patients, for instance, as proposed by a recent commentary on the American Society of Clinical Oncology update on palliative care for cancer patients (Crowley et al. 2024).

Strengths and limitations

The EDIUM study is being conducted in Colorectal Cancer Centres in Germany, Austria and Switzerland that are certified by the German Cancer Society. Certified centres meet a number of quality requirements and have better oncological outcomes on average than uncertified units (Schmitt et al. 2023). The documentation of clinical characteristics across certified centres is standardized and reviewed annually for certification purposes, ensuring data validity and reliability. However, the results may not be generalizable beyond certified centres. In addition, the use of scores and cut-off

values in this study may not fully capture the patients' pain status. The thresholds used are established based on population averages but may not account for variability in the population.

A recent review by Hasson et al. (Hasson et al. 2020) identifies research gaps in the field of palliative care and in particular highlights how difficult the recruitment of palliatively treated cancer patients for research generally is. For EDIUM as well, the centres reported having difficulties in including these patients in the study. This may limit the representativeness of the study population. For example, it might explain the age difference between the study population presented here and the overall colorectal cancer population in Germany. The younger mean age in the study population may perhaps be a result of the willingness of severely ill cancer patients to participate in studies while already receiving palliative care. Since an older palliatively treated population would be expected to be even more burdened by pain, the study may still underestimate the true burden and needs of these patients (Finnerty et al. 2019). A further limitation is the lack of information on the sites of metastases, pain medication, or other treatments like radiotherapy administered outside the certified centre, potentially affecting the patient's pain trajectory.

Conclusion

The results presented here show high levels of pain among colorectal cancer patients 12 months after the initiation of treatment, with low quality of life values. Yet symptom control and an improved quality of life, as defined in the palliative care guidelines, do not appear to be achieved. To follow oncologic guidelines for palliatively treated cancer patients, adequate symptom management is needed to improve the patients' quality of life. To make it possible to provide adequate symptom-specific care and improve quality of life for patients with higher-stage cancer, symptom relief, including pain, should be monitored more closely. To improve the care of palliatively treated colorectal cancer patients, tailored care that considers the individual needs of cancer patients is crucial. Future research needs to focus on specific needs for adequate pain management, taking into account palliative treatment options and possible other factors such as clinical variables and patient characteristics.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00432-025-06186-x>.

Author contributions Data analysis was performed by NTS and SKS. The first draft of the manuscript was written by SKS and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. NTS and CK supervised this work.

Funding Open Access funding enabled and organized by Projekt DEAL.

The EDIUM study was funded by the Innovation Committee of the Federal Joint Committee (G-BA) from 2018 to 2021.

Data availability The data that support the findings of this study are not openly available due to data policy framework of the EDIUM study. Aggregated data can be requested from the corresponding author.

Declarations

Ethical approval The study was advised and approved by the ethics committee of the Berlin Medical Association (Eth-19/18). All the patients gave written consent for their participation in the study.

Competing interests CK, NTS, CB, SKS are employees of the German Cancer Society (DKG). SB and TS are members of the Scientific Advisory Board of the DKG. TS is a Board Member of the DKG. VK is employee of ClarData and OnkoZert, the certifying body of the German Cancer Society. JB has received payments for a lecture by Coloplast; has received support for travel and accommodations from Intuitive Surgical and is part of the EsmAil Trial Advisory Board. JO has received a study grant from the Federal Joint Committee in Germany. DW received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for the German Society for General and Visceral Surgery and Medtronic. PAN received grants or contracts from the German Cancer Association, for the German Research Foundation Project, the Albrecht Stuppeler Clinician Scientist Fellowship, the Bavarian Research Foundation and B. Braun Foundation; received payments for lectures from Johnson&Johnson and Dr. Falk; received a travel grant for a congress from Johnson& Johnson (payment was made to the institution); was part of the Advisory Board Johnson&Johnson. All other authors have declared no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJMd, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European organization for research and treatment of cancer QLQ-C30: A Quality-of-Life instrument for use in international clinical trials in oncology. *JNCI J Natl Cancer Inst* 85(5):365–376. <https://doi.org/10.1093/jnci/85.5.365>
- Crowley F, Smith CB, Arnold RM, Afezoli D (2024) American Society of Clinical Oncology guideline update on palliative care

- for patients with cancer: Addressing the reality gap. *Cancer*, cncr.35656. <https://doi.org/10.1002/cncr.35656>
- Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, Kowalski C, Perrone F, Stover AM, Sundaresan P, Warrington L, Zhang L, Apostolidis K, Freeman-Daily J, Ripamonti CI, Santini D (2022) The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. *Ann Oncol* 0923753422006913. <https://doi.org/10.1016/j.anonc.2022.04.007>
- Drury A, Payne S, Brady A-M (2017) The cost of survival: an exploration of colorectal cancer survivors' experiences of pain. *Acta Oncol* 56(2):205–211. <https://doi.org/10.1080/0284186X.2016.1266084>
- Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring Manual (3).
- Finnerty D, O'Gara Á, Buggy DJ (2019) Managing pain in the older cancer patient. *Curr Oncol Rep* 21(11):100. <https://doi.org/10.1007/s11912-019-0854-7>
- Flyum IR, Mahic S, Grov EK, Joranger P (2021) Health-related quality of life in patients with colorectal cancer in the palliative phase: A systematic review and meta-analysis. *BMC Palliat Care* 20(1):144. <https://doi.org/10.1186/s12904-021-00837-9>
- German Guideline Programme in Oncology (2015) Evidenced-based Guideline: Palliative care for patients with incurable cancer, AWMF-registration number 128/001OL
- German Guideline Program in Oncology (2019) S3-Guideline Colorectal Cancer, long version 2.1, AWMF registrationnumber: 021-007OL
- Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Effiace F, Groenvold M, van Leeuwen M, Petersen M, Aa., Ramage J, Tomaszewski KA, Young T, Holzner B (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. *J Clin Epidemiol* 118:1–8. <https://doi.org/10.1016/j.jclinepi.2019.10.003>
- Hasson F, Nicholson E, Muldrew D, Bamidele O, Payne S, McIlpatrick S (2020) International palliative care research priorities: A systematic review. *BMC Palliat Care* 19(1):16. <https://doi.org/10.1186/s12904-020-0520-8>
- Kenzik K, Pisu M, Johns S, Baker T, Oster R, Kvale E, Fouad M, Martin M (2015) Unresolved pain interference among colorectal cancer survivors: implications for patient care and outcomes. *Pain Med* 16(7):1410–1425. <https://doi.org/10.1111/pme.12727>
- Kowalski C, Sibert NT, Wesselmann S (2022) Outcome quality after colorectal cancer resection in certified colorectal cancer centers. *Deutsches Ärzteblatt International* 119(48):821–828. <https://doi.org/10.3238/arztebl.m2022.0325>
- Lüdecke D, Ben-Shachar M, Patil I, Waggoner P, Makowski D (2021) Performance: an R package for assessment, comparison and testing of statistical models. *J Open Source Softw* 6(60):3139. <https://doi.org/10.21105/joss.03139>
- Musoro JZ, Sodergren SC, Coens C, Pochesci A, Terada M, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner H-H, Bottomley A (2020) Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. *Colorectal Dis* 22(12):2278–2287 & the EORTC Quality of Life, Gastro-intestinal Groups. <https://doi.org/10.1111/codi.15295>
- Raina R, Krishnappa V, Gupta M (2018) Management of pain in end-stage renal disease patients: short review. *Hemodial Int* 22(3):290–296. <https://doi.org/10.1111/hdi.12622>
- Robert Koch-Institut (2023) Krebs in Deutschland für 2019/2020. 14. Ausgabe. <https://doi.org/10.25646/11357>
- Rodriguez C, Ji M, Wang H-L, Padhya T, McMillan SC (2019) Cancer pain and quality of life. *J Hospice Palliat Nurs* 21(2):116–123. <https://doi.org/10.1097/NJH.0000000000000507>
- Sanders JJ, Temin S, Ghoshal A, Alesi ER, Ali ZV, Chauhan C, Cleary JF, Epstein AS, Firn JI, Jones JA, Litzow MR, Lundquist D, Mardones MA, Nipp RD, Rabow MW, Rosa WE, Zimmermann C, Ferrell BR (2024) Palliative care for patients with cancer: ASCO guideline update. *J Clin Oncol* 42(19):2336–2357. <https://doi.org/10.1200/JCO.24.00542>
- Schmitt J, Klinkhammer-Schalke M, Bierbaum V, Gerken M, Bobeth C, Rößler M, Dröge P, Ruhnke T, Günster C, -van Kleihues K, Schoffer O (2023) Initial cancer treatment in certified versus non-certified hospitals. *Deutsches Ärzteblatt International*. <https://doi.org/10.3238/arztebl.m2023.0169>
- Scott NW, Fayers P, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers MA, Group E (2008) Q. of L. EORTC QLQ-C30 Reference Values Manual. 2nd ed. Brussels, Belgium, 427
- Sjoberg DD (2021) Ggsankey [Computer software]. <https://github.com/davidsjoberg/ggsankey?tab=readme-ov-file>
- Sjoberg DD, Lamarange MC, Lavery J, Whiting K, Zabor EC (2020) Tbl_summary (Version 1.7.2) [Computer software]. https://cran.r-project.org/web/packages/gtsummary/vignettes/tbl_summary.html
- Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, Johnson CD, Pilkington SA, Arraras J, Ben-Josef E, Pullyblank AM, Fayers P, Blazeby JM (2009) Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. *Eur J Cancer* 45(17):3017–3026. <https://doi.org/10.1016/j.ejca.2009.08.014>
- Wilson BE, Booth CM, Patel S, Berry S, Kong W, Merchant SJ (2023) First-line palliative chemotherapy for colorectal cancer: A Population-based analysis of delivery and outcomes in a Single-payer health system. *Clin Oncol* S093665523004600. <https://doi.org/10.1016/j.clon.2023.12.003>
- Wintner LM, Sztankay M, Giesinger JM, Aaronson N, Bottomley A, Velikova G, Verdonck de Leeuw I, van de Poll-Franse L, Groenvold M, Aagard Petersen M, Holzner B, EORTC Quality of Life Group (2016) & on behalf of the. EORTC Quality of Life Group manual for the use of EORTC measures in daily clinical practice
- Zerillo JA, Schouwenburg MG, van Bommel ACM, Stowell C, Lippa J, Bauer D, Berger AM, Boland G, Borrás JM, Buss MK, Cima R, Van Cutsem E, van Duyn EB, Finlayson SRG, Hung-Chun Cheng S, Langelotz C, Lloyd J, Lynch AC, Mamon HJ, the Colorectal Cancer Working Group of the International Consortium for Health Outcomes Measurement (ICHOM) (2017)... for. An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer. *JAMA Oncology*, 3(5), 686. <https://doi.org/10.1001/jamaonc.2017.0417>
- Zielińska A, Włodarczyk M, Makaro A, Sałaga M, Fichna J (2021) Management of pain in colorectal cancer patients. *Crit Rev Oncol/Hematol* 157:103122. <https://doi.org/10.1016/j.critrevonc.2020.103122>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Sophie Klara Schellack¹ · Clara Breidenbach¹ · Christoph Kowalski¹ · Ulrich Wedding² · Birgitt van Oorschot³ · Thomas Seufferlein⁴ · Stefan Benz⁵ · Martin Schnell⁶ · Jörg Köninger⁷ · Christina Klein⁸ · Johann Ockenga⁹ · Björn Freitag¹⁰ · Uwe A. Wittel¹¹ · Roger Wahba¹² · Mia Kim¹³ · Saleem Elhabash¹⁴ · Pompiliu Piso¹⁵ · Dirk Weyhe¹⁶ · Jörg Bunse¹⁷ · Maren Riechmann¹⁸ · Marco von Strauss¹⁹ · Sebastian Petzoldt²⁰ · Philipp-Alexander Neumann²¹ · Vanessa Kolb²² · Nora Tabea Sibert^{1,23}

✉ Nora Tabea Sibert
noratabea.sibert@med.uni-duesseldorf.de

Sophie Klara Schellack
schellack@krebsgesellschaft.de

¹ German Cancer Society, Kuno-Fischer-Straße 8, 14057 Berlin, Germany

² University Medicine Jena, Kastanienstraße 1, 07747 Jena, Germany

³ University of Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany

⁴ University Medicine Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany

⁵ Klinikum Sindelfingen-Böblingen, Calwer Straße 68, 71034 Böblingen, Germany

⁶ Hegau-Bodensee-Klinikum Singen, Virchowstr. 10, 78224 Singen, Germany

⁷ Klinikum Stuttgart, Kriegsbergstraße 60, 70174 Stuttgart, Germany

⁸ Helios Park-Klinikum Leipzig, Strümpellstraße 41, 04289 Leipzig, Germany

⁹ Bremen Klinikum Bremen-Mitte, Sankt-Jürgen-Str. 1, 28205 Bremen, Germany

¹⁰ St. Josef-Hospital, Gudrunstraße 56, 44791 Bochum, Germany

¹¹ Kliniken Nordoberpfalz– Klinikum Weiden, Söllnerstraße 16, 92637 Weiden in der Oberpfalz, Germany

¹² Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany

¹³ München Klinik Neuperlach, Sanatoriumspl. 2, 81545 München, Germany

¹⁴ Johannes Wesling Klinikum Minden, Hans-Nolte-Straße 1, 32429 Minden, Germany

¹⁵ Barmherzige Brüder Regensburg, Prüfeninger Str. 86, 93049 Regensburg, Germany

¹⁶ Pius Hospital University Medicine Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany

¹⁷ Sana Klinikum Lichtenberg, Fanningerstraße 32, 10365 Berlin-Lichtenberg, Germany

¹⁸ Sana Klinikum Hof, Hochfranken, Eppenreuther Straße 9, 95032 Hof, Germany

¹⁹ St. Claraspital Basel, Kleinriedenstrasse 30, Basel 4058, Switzerland

²⁰ DRK Kliniken Berlin-Treptow– Köpenick, Salvador-Allende-Str. 2– 8, 12559 Berlin, Germany

²¹ Klinikum rechts der Isar, TUM University Hospital, TU Munich, Ismaninger Str. 22, Munich, Germany

²² OnkoZert GmbH, Gartenstraße 24, Neu-Ulm, Germany

²³ Oncological Health Services Research with a focus on Digital Medicine, Department of Gynaecology and Obstetrics, CIO ABCD, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Moorenstraße 5, Düsseldorf, Germany